Search

Displaying results 2711 - 2720 of 3917 in total
  1. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833]

  2. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  3. Drug

    Recombinant human plasma gelsolin

    go.drugbank.com/drugs/DB15746
    Investigational

    Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.

  4. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540].

  5. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.

  6. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

  7. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]

  8. Drug

    Cupric sulfate

    go.drugbank.com/drugs/DB06778
    Approved

    Interestingly, the dysregulation of copper has been studied with a focus on neurodegenerative diseases, such as Wilson’s disease, Alzheimer’s disease, and Parkinson’s disease.

  9. Drug

    Queuine

    go.drugbank.com/drugs/DB14732
    ExperimentalNutraceutical

    Bacteria possess the exclusive ability to synthesize queuine, which is then salvaged and passed on to plants and animals.

  10. Drug

    SIG-205

    go.drugbank.com/drugs/DB18548
    Experimental

    SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer